Clinical trial NCT04698057: Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.
Official title: Amoxicillin-clavulanate Alone or in Combination With Ciprofloxacin in Low-Risk Febrile Neutropenic Adult Patients: A Prospective, Double-blind, Randomized, Non-Inferiority Multicenter, Phase III Clinical Trial.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE3
Conditions: Febrile Neutropenia
Lead sponsor: Poitiers University Hospital
Sponsor class: OTHER
First posted: 2021-01-06
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 110
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In low risk neutropenic fever in cancer, standard of care is the association of amoxicillin clavulanate and ciprofloxacin. But in this population, the rate of fever related to infection is very low, leading to a overtreatment of the patients. The aim of this study is to validate a descalation of the antibiotherapy with safety concerns.


Eligibility criteria: Inclusion Criteria:

* Patient ≥ 18 years old
* Treated for a solid cancer or a hematological malignancy
* Presented with low-risk\* febrile neutropenia due to chemotherapy with an expected duration of neutropenia ≤ 7 days
* Neutropenia is defined by an absolute neutrophil count ≤ 500/mm3.
* Fever is defined by temperature ≥ 38.3° or ≥ 38° twice during a 1-hour interval.
* Signing informed consent \*Low risk is defined by MASCC score ≥ 21

Exclusion Criteria:

* Hypersensitivity to the active substances: amoxicillin-clavulanic, ciprofloxacin, penicillins, to other quinolones or to one of the excipient
* History of severe immediate hypersensitivity reaction to another beta-lactam
* History of jaunditis/hepatic impairment related to amoxicillin/clavulanic
* Concomitant administration of ciprofloxacin and tizanidine.
* Clinical signs of focal infection including history of untreated dental abscess.
* Signs of sepsis or organ failure.
* Severe immune deficiency other than the current cancer, except controlled-HIV infection
* Gastrointestinal symptoms requiring intravenous treatment (mucositis, vomiting, severe diarrhea...).
* Known aminotransferase serum levels \> 5 x normal values.
* Known renal insufficiency defined as creatinine clearance of \< 30 mL/min (MDRD).
* Antibiotherapy within 24h before enrollment. Prophylactic use of amoxicillin is an exclusion criterium whereas prophylactic use of trimethoprim-sulfamethoxazole (cotrimoxazole) and penicillin G (Oracilline®) are not and will be considered in the analysis.
* History of infection or colonization due to bacteria resistant to experimental drugs in the previous year
* Can be enrolled in the study only once.
* Patients not benefiting from a Social Security scheme or not benefiting from it through a third party.
* Persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergencies
* Pregnant or breastfeeding women, women at age to procreate and not using effective contraception (either hormonal / mechanical : oral, injection, subcutaneous, implantable, intrauterine device, or surgical : tubal ligation, hysterectomy, total ovariectomy).

Primary outcomes:
measure: Success rate
timeFrame: 7 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: